Van Cleef Asset Management Inc Sells 200 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Van Cleef Asset Management Inc lowered its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.9% in the fourth quarter, HoldingsChannel reports. The firm owned 10,215 shares of the biopharmaceutical company’s stock after selling 200 shares during the period. Van Cleef Asset Management Inc’s holdings in Gilead Sciences were worth $828,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of GILD. OFI Invest Asset Management bought a new stake in shares of Gilead Sciences during the third quarter worth approximately $26,000. Tompkins Financial Corp raised its position in shares of Gilead Sciences by 223.1% in the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 241 shares in the last quarter. Fortitude Family Office LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $29,000. Rakuten Securities Inc. acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $33,000. Finally, Financial Connections Group Inc. acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $40,000. Institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the subject of several research analyst reports. Oppenheimer reiterated an “outperform” rating and set a $105.00 price target on shares of Gilead Sciences in a report on Friday, April 19th. UBS Group dropped their price objective on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Wells Fargo & Company lowered their target price on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a report on Monday, March 4th. StockNews.com lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, April 19th. Finally, Cantor Fitzgerald decreased their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research note on Wednesday, February 7th. Ten investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $84.57.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the transaction, the insider now owns 96,304 shares in the company, valued at approximately $7,026,339.84. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Stock Performance

GILD traded down $1.81 on Thursday, hitting $65.27. The company’s stock had a trading volume of 15,163,484 shares, compared to its average volume of 7,415,576. The company’s 50 day simple moving average is $71.56 and its 200-day simple moving average is $76.39. The firm has a market cap of $81.27 billion, a P/E ratio of 14.98, a price-to-earnings-growth ratio of 0.96 and a beta of 0.19. Gilead Sciences, Inc. has a 12 month low of $65.09 and a 12 month high of $87.86. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, beating the consensus estimate of ($1.49) by $0.17. The firm had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The business’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the company posted $1.37 EPS. Analysts forecast that Gilead Sciences, Inc. will post 5.24 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were given a dividend of $0.77 per share. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.72%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. Gilead Sciences’s dividend payout ratio (DPR) is 68.44%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.